Neoantigens in cancer immunotherapy: focusing on alternative splicing

被引:5
|
作者
Huang, Peng [1 ,2 ]
Wen, Feng [1 ,3 ]
Tuerhong, Nuerye [1 ,2 ]
Yang, Yang [1 ,2 ]
Li, Qiu [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Canc Ctr, Dept Radiat Oncol, Chengdu, Sichuan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
alternative splicing; neoantigen; cancer; immunotherapy; CAR-T; MECHANISMS; BREAST; IDENTIFICATION; MUTATIONS; THERAPIES; PD-L1; GENE;
D O I
10.3389/fimmu.2024.1437774
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Alternative splicing (AS) functions as a crucial program in transcriptional modulation, leading to proteomic diversity and functional alterations of proteins. These splicing actions induce various neoantigens that hold prognostic significance and contribute to various aspects of cancer progression, including immune responses against cancer. The advent of immunotherapy has remarkably revolutionized tumor therapy. In this regard, AS-derived neoantigens are potent targets for cancer vaccines and chimeric antigen receptor (CAR) T cell therapies. In this review, we outline that AS-derived neoantigens serve as promising immunotherapeutic targets and guide immunotherapy strategies. This evidence contributes to a deeper comprehension of the complexity of proteomic diversity and provides novel perspectives and techniques for precision medicine in immunotherapy. Moreover, we underscore the obstacles that are awaited to be addressed for this novel approach to become clinically applicable.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
    Verdon, Daniel J.
    Jenkins, Misty R.
    CANCERS, 2021, 13 (16)
  • [42] Chemically inducible splice-neoantigens for cancer immunotherapy
    Matsushima, Shingo
    Ajiro, Masahiko
    Iida, Kei
    Chamoto, Kenji
    Honjo, Tasuku
    Hagiwara, Masatoshi
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Immune targets and neoantigens for cancer immunotherapy and precision medicine
    Rong-Fu Wang
    Helen Y Wang
    Cell Research, 2017, 27 : 11 - 37
  • [44] Alternative Splicing and Cancer
    Auboeuf, Didier
    Carmo-Fonseca, Maria
    Valcarcel, Juan
    Biamonti, Giuseppe
    JOURNAL OF NUCLEIC ACIDS, 2012, 2012
  • [45] Comprehensive profiling of cancer neoantigens from aberrant RNA splicing
    Wickland, Daniel P.
    McNinch, Colton
    Jessen, Erik
    Necela, Brian
    Shreeder, Barath
    Lin, Yi
    Knutson, Keith L.
    Asmann, Yan W.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [46] Identification of neoantigens for immunotherapy
    Braeunlein, Eva
    Krackhardt, Angela M.
    ONKOLOGE, 2021, 27 (11): : 1109 - 1113
  • [47] Alternative transcription and alternative splicing in cancer
    Pal, Sharmistha
    Gupta, Ravi
    Davuluri, Ramana V.
    PHARMACOLOGY & THERAPEUTICS, 2012, 136 (03) : 283 - 294
  • [48] Neoantigens in precision cancer immunotherapy: from identification to clinical applications
    Zhang, Qiao
    Jia, Qingzhu
    Zhang, Jing
    Zhu, Bo
    CHINESE MEDICAL JOURNAL, 2022, 135 (11) : 1285 - 1298
  • [49] Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
    Efremova, Mirjana
    Finotello, Francesca
    Rieder, Dietmar
    Trajanoski, Zlatko
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [50] RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines
    Shen, Luhui
    Zhang, Jian
    Lee, Hojoon
    Batista, Milene Tavares
    Johnston, Stephen Albert
    SCIENTIFIC REPORTS, 2019, 9 (1)